Boothbay Fund Management, LLC Gemini Therapeutics, Inc. Transaction History

Boothbay Fund Management, LLC

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$3.3 - $6.32 $17,836 - $34,159	-5,405 Reduced 11.33%	42,297 $171,000
Q2 2021 Aug 16, 2021	SELL	$6.32 - $14.02 $182,325 - $404,462	-28,849 Reduced 37.69%	47,702 $309,000
Q1 2021 May 17, 2021	BUY	$11.32 - $18.0 $866,557 - $1.38 Million	76,551 New	76,551 $1.04 Million

2.44M

Ticker GMTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,244,500
Market Cap $1.05B
Description
Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 ...

Get notified when there are updates to the investment portfolio of Boothbay Fund Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Boothbay Fund Management, LLC with notifications on news.